Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06041256 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1)
A Phase 1 study, sponsored by Aurion Biotech.
- Completed
- Registry status
- Phase 1
- Development phase
- 97
- Enrollment target
NCT06041256 is a Phase 1 study that has completed, run by Aurion Biotech. The registered enrollment target is 97 participants.
The verdict
NCT06041256, a Phase 1 study, has completed, sponsored by Aurion Biotech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 97 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to compare different doses of AURN001 in patients with corneal edema secondary to corneal endothelial dysfunction. The main questions the clinical trial aims to answer are whether AURN001 effective and safe. Participants will receive a single injection of AURN001. A comparison between low, medium, and high doses of AURN001 against the contribution of each element, cells alone and Y27632 alone, will be conducted to determine the effects on corneal edema.
Interventions
- COMBINATION_PRODUCT AURN001
- BIOLOGICAL Corneal Endothelial Cells
- DRUG Y27632
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2023-10-18 |
| Est. Completion | 2025-04-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06041256
The ClinicalTrials.gov registry entry for NCT06041256 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aurion Biotech, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which AURN001 is the first listed.
NCT06041256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06041256 about?
NCT06041256 is a clinical study titled "A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1)". The goal of this clinical trial is to compare different doses of AURN001 in patients with corneal edema secondary to corneal endothelial dysfunction. The main questions the clinical trial aims to answer are whether AURN001 effective and safe. Participants will receive a single injection of AURN001. ...
What is the current status of trial NCT06041256?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 97 participants. The study started on 2023-10-18. Estimated completion is 2025-04-15.
What interventions are being tested in trial NCT06041256?
The interventions under investigation include: AURN001 (COMBINATION_PRODUCT), Corneal Endothelial Cells (BIOLOGICAL), Y27632 (DRUG).
Who is sponsoring clinical trial NCT06041256?
This trial is sponsored by Aurion Biotech, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.